Q2 EPS Estimates for Krystal Biotech Raised by HC Wainwright

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Krystal Biotech to $1.59 (from $1.37) and reaffirmed a "Buy" rating with a $310 target, while other analysts have also lifted targets leaving a consensus price target near $326.25.
• Krystal beat Q1 expectations, reporting $1.83 EPS vs. $1.45 consensus and $116.4M revenue with a 52.6% net margin and roughly $1.0B in cash, and management expects multiple pipeline readouts in 2026 (including registrational readouts for KB803 and KB801) plus FDA platform designations for other programs.
• Market reaction and ownership dynamics: KRYS stock rallied (up ~7.1%), valuing the company at about $8.4B, but insiders have sold shares recently (129,164 shares, ~$34.5M) while institutional investors own ~86.3% of the stock, which investors should weigh alongside the positive catalysts.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at HC Wainwright raised their Q2 2026 EPS estimates for Krystal Biotech in a research note issued on Monday, May 4th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $1.59 per share for the quarter, up from their prior estimate of $1.37. HC Wainwright currently has a "Buy" rating and a $310.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $7.58 per share. HC Wainwright also issued estimates for Krystal Biotech's Q3 2026 earnings at $1.74 EPS and Q4 2026 earnings at $1.74 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping analysts' consensus estimates of $1.45 by $0.38. The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%.

A number of other brokerages have also recently commented on KRYS. Guggenheim upped their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Citigroup reaffirmed a "buy" rating on shares of Krystal Biotech in a research report on Tuesday. Jefferies Financial Group upped their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th. Wolfe Research started coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They set a "peer perform" rating on the stock. Finally, Chardan Capital upped their price target on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a "buy" rating in a research report on Wednesday, February 18th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Krystal Biotech has an average rating of "Moderate Buy" and a consensus target price of $326.25.

Krystal Biotech Stock Up 7.1%

KRYS stock opened at $284.93 on Tuesday. The firm has a market cap of $8.39 billion, a price-to-earnings ratio of 41.60 and a beta of 0.50. The company's fifty day simple moving average is $261.72 and its 200 day simple moving average is $246.50. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $298.30.

Insider Activity at Krystal Biotech

In other news, CAO Kathryn Romano sold 12,500 shares of the company's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer owned 19,318 shares in the company, valued at approximately $5,257,200.52. This represents a 39.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Dino A. Rossi sold 18,950 shares of the company's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the transaction, the director owned 78,691 shares in the company, valued at $20,570,614.31. This represents a 19.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 129,164 shares of company stock worth $34,538,578 over the last three months. 13.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently made changes to their positions in KRYS. Soleus Capital Management L.P. raised its holdings in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company's stock worth $126,870,000 after acquiring an additional 481,200 shares during the last quarter. Norges Bank acquired a new stake in shares of Krystal Biotech in the 4th quarter worth about $70,159,000. William Blair Investment Management LLC raised its holdings in shares of Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company's stock worth $92,783,000 after acquiring an additional 227,038 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Krystal Biotech by 2,078.9% in the 4th quarter. Janus Henderson Group PLC now owns 219,440 shares of the company's stock worth $54,147,000 after acquiring an additional 209,369 shares during the last quarter. Finally, UBS Group AG raised its holdings in shares of Krystal Biotech by 970.8% in the 4th quarter. UBS Group AG now owns 159,595 shares of the company's stock worth $39,347,000 after acquiring an additional 177,922 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech News Roundup

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q1 results beat estimates — KRYS reported $1.83 EPS vs. $1.45 consensus and $116.4M revenue (above estimates), with a 52.6% net margin, supporting the view of profitable growth. Zacks Article
• Positive Sentiment: Strong commercial traction — VYJUVEK global revenue was $116.4M in Q1 and $846.7M cumulative since launch, signaling continued commercial momentum and revenue durability. GlobeNewswire Press Release
• Positive Sentiment: Pipeline catalysts and de‑risking readouts — Management flagged enrollment complete for KB803 and on‑track registrational readouts for KB803 and KB801 in 2026, and the company expects multiple (reported as six) data readouts this year — potential major binary upside if positive. Yahoo Finance
• Positive Sentiment: Regulatory and platform progress — FDA granted platform technology designation for KB407 (CF) and KB111 (HHD), which may streamline future regulatory engagement and add strategic value to the gene‑therapy platform. GlobeNewswire Press Release
• Positive Sentiment: Strong balance sheet — Company ended the quarter with approximately $1.0B in cash and investments, supporting commercialization, multiple readouts and potential execution on pipeline programs. GlobeNewswire Press Release
• Positive Sentiment: Analyst support — HC Wainwright reaffirmed a "buy" rating and $310 target, providing an analyst-level upside case and helping sentiment. Benzinga Note
• Neutral Sentiment: Market reaction and coverage — The stock rallied following the print (reported >6% intraday on some outlets) as investors digested the beat and pipeline timeline; watch upcoming readout dates for further moves. Investing.com
• Neutral Sentiment: Full disclosures and call materials available — Earnings call transcript, slide deck and company press release are published for deeper review by investors. Seeking Alpha Transcript Slide Deck

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.